Dr. Dipti Patel's Credentials

Accepting New Patients

Yes, this doctor is accepting new patients

Biography

Dr. Patel-Donnelly is triple board-certified in medical oncology, hematology, and internal medicine. She completed her fellowship in Medical Oncology and Hematology at the Dana-Farber Cancer Institute/Brigham and Women's Hospital/Massachusetts General Hospital at Harvard Medical School. Dr. Patel-Donnelly received her Doctorate of Medicine and completed her Internal Medicine Internship and Residency from the Mount Sinai School of Medicine in New York, New York, and she is a magna cum laude graduate in biochemistry with honors and independent research from Binghamton University in Binghamton, New York. Dr. Patel-Donnelly has taken an active role at Virginia Cancer Specialists and in the local and medical communities. Dr. Patel-Donnelly holds memberships and appointments in multiple organizations. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Society of Hematology, and the Medical Society of Virginia. Focusing on a special interest in hematologic malignancies, brain tumors, and stem cell transplant, Dr. Patel-Donnelly has become highly involved in local tumor boards and currently serves as Section Chief of Hematology/Oncology at Inova Fairfax Hospital and holds a Hematology/Oncology Faculty Clerkship appointment at Virginia Commonwealth University. Dr. Patel-Donnelly has also received multiple awards and honors which include the Harvard Partners in Excellence Award, Excellence in Teaching Awards, National Institutes of Health Research Fellowship, NASE Achievement Scholarship, and Distinguished Honors and Independent Research in Biochemistry. Dr. Patel-Donnelly has been consistently named as a Top Doctor in publications such as Northern Virginia Magazine and Washingtonian magazine. Additionally, she has been listed as a Castle Connolly Mid-Atlantic Top Doctor and a Washington Post Super Doctor. Dr. Patel-Donnelly is a published author and has spoken both at local educational events and in news interviews. Dr. Patel-Donnelly lives in Northern Virginia with her husband and two children. She is married to Dr. Donnelly at Georgetown University Medical Center whose expertise is in Internal Medicine and Pediatrics. She enjoys spending time with her family, cooking, running, traveling, and reading.

Languages

• Hindi
• Gujarati
• English

Education

• Binghamton University (Grad. 1992)
• Mount Sinai School Of Medicine Of City University Of New York (Grad. 1996)

Other Specialties

• Oncologist / Hematologist

Areas of Expertise

• Leukemia
• Lymphoma
• Brain tumor
• Oncology
• Multiple myeloma

Awards & Recognitions

• Washingtonian Magazine Top Doctors 2017
• Castle Connolly Top Doctors 2017
• Castle Connolly Top Doctors 2014
• Washingtonian Top Doctor 2014
• Castle Connolly Top Doctors 2013
• Northern Virginia Magazine Top Doctor 2019
• Washington Magazine Top Doctors 2020
• Castle Connolly Top Doctors 2012
• Castle Connolly Top Doctors 2016
• Castle Connolly Top Doctors 2018
• Northern Virginia Magazine Top Doctor 2013
• 2018 Washingtonian Magazine Top Doctor Nomination
• Castle Connolly Top Doctors 2015
• Northern Virginia Magazine Top Doctors 2018
• Castle Connolly Top Doctors 2019
• Castle Connolly Top Doctors 2020
• 2020 Northern Virginia Magazine Top Doctors
• Washingtonian Top Doctor 2016

Publications & Research

• Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy
• Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
• Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Clinical Studies in Hodgkin Lymphoma
• Entospletinib Monotherapy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Previously Treated With B-cell Receptor Inhibitors: Results of a Phase 2 Study
• Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL
• WALDENSTRÖM'S MACROGLOBULINEMIA MASQUERADING AS BIRDSHOT CHORIORETINOPATHY.
• Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study
• Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients
• An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
• Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
• The dynamics of GPIIb/IIIa-mediated platelet-platelet interactions in platelet adhesion/thrombus formation on collagen in vitro as revealed by videomicroscopy
• An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
• Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline
• Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).
• Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study